科研成果详情

题名Discovery of the Diphenyl 6-Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the JNK2-NF-κB/MAPK Pathway
作者
发表日期2023-08-29
发表期刊Journal of medicinal chemistry   影响因子和分区
语种英语
原始文献类型Journal Article
其他关键词ANTIINFLAMMATORY AGENTS ; DERIVATIVES ; DESIGN ; POTENT ; ALPHA ; LPS
摘要Acute lung injury (ALI) and sepsis are both serious and complex conditions associated with high mortality, yet there are no effective treatments. Herein, we designed and synthesized a series of diphenyl 6-oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide analogues exhibiting anti-inflammatory activity. The optimal compound J27 decreased the release of TNF-α and IL-6 in mouse and human cells J774A.1 and THP-1 (IL-6 IC50 = 0.22 μM) through the NF-κB/MAPK pathway. J27 demonstrated remarkable protection against ALI and sepsis in vivo and exhibited good safety in subacute toxicity experiments. Pharmacokinetic study indicated that J27 had good bioavailability (30.74%). To our surprise, J27 could target JNK2 with a totally new molecular skeleton compared with the only few JNK2 inhibitors reported. Moreover, there is no report that JNK2 inhibitors could apply for ALI and sepsis. Therefore, this work provides a new lead structure for the study of JNK2 inhibitors and a new target of JNK2 to treat ALI and sepsis
资助项目Zhejiang Provincial Key Scientific Project[2021C03041];Wenzhou Medical University[QTJ21013];National Natural Science Funding of China[21961142009,82273791];Thailand Research Fund[DBG6280006];University of Chinese Academy of Sciences[WIUCASQD2020016];
出版者AMER CHEMICAL SOC
ISSN0022-2623
EISSN1520-4804
卷号66期号:17页码:12304-12323
DOI10.1021/acs.jmedchem.3c00832
页数20
WOS类目Chemistry, Medicinal
WOS研究方向Pharmacology & Pharmacy
WOS记录号WOS:001190512100001
收录类别PUBMED ; SCOPUS ; SCIE
在线发表日期2023-08
URL查看原文
PubMed ID37643372
SCOPUSEID2-s2.0-85171309534
自科自定义期刊分类T3(B)类
通讯作者地址[Liang, Guang]Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China ; [Tang, Qidong]Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China
Scopus学科分类Molecular Medicine;Drug Discovery
TOP期刊TOP期刊
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/182528
专题药学院(分析测试中心)
药学院(分析测试中心)_生物有机与药物化学研究中心
通讯作者Liang, Guang; Tang, Qidong
作者单位
1.Chemical Biology Research Center,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,325035,China;
2.School of Pharmacy,Hangzhou Medical College,Hangzhou,311399,China;
3.Wenzhou Institute,University of Chinese Academy of Sciences,Wenzhou,325024,China;
4.College of Pharmacy,Chonnam National University,Gwangju,61186,South Korea
第一作者单位药学院(分析测试中心);  生物有机与药物化学研究中心
通讯作者单位药学院(分析测试中心);  生物有机与药物化学研究中心
第一作者的第一单位药学院(分析测试中心)
推荐引用方式
GB/T 7714
Liao, Jing,Yang, Jun,Li, Xiaobo,et al. Discovery of the Diphenyl 6-Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the JNK2-NF-κB/MAPK Pathway[J]. Journal of medicinal chemistry,2023,66(17):12304-12323.
APA Liao, Jing., Yang, Jun., Li, Xiaobo., Hu, Chenghong., Zhu, Weiwei., ... & Tang, Qidong. (2023). Discovery of the Diphenyl 6-Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the JNK2-NF-κB/MAPK Pathway. Journal of medicinal chemistry, 66(17), 12304-12323.
MLA Liao, Jing,et al."Discovery of the Diphenyl 6-Oxo-1,6-dihydropyridazine-3-carboxylate/carboxamide Analogue J27 for the Treatment of Acute Lung Injury and Sepsis by Targeting JNK2 and Inhibiting the JNK2-NF-κB/MAPK Pathway".Journal of medicinal chemistry 66.17(2023):12304-12323.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Liao, Jing]的文章
[Yang, Jun]的文章
[Li, Xiaobo]的文章
百度学术
百度学术中相似的文章
[Liao, Jing]的文章
[Yang, Jun]的文章
[Li, Xiaobo]的文章
必应学术
必应学术中相似的文章
[Liao, Jing]的文章
[Yang, Jun]的文章
[Li, Xiaobo]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。